不同药物在膀胱灌注治疗浅表性膀胱癌中的效果比较  

Comparison of the effect of different drugs by bladder instillation in treatment with superficial bladder cancer

作　　者：马晋[1] 范地兵 廖凯[1] 

机构地区：[1]广元市第一人民医院泌尿科,四川广元628017

出　　处：《四川医学》2013年第1期104-105,共2页Sichuan Medical Journal

摘　　要：目的比较吡柔比星(THP)、丝裂霉素C(MMC)在膀胱灌注治疗浅表性膀胱癌中的效果。方法 2009年1月～2011年1月,68例术后浅表性膀胱癌患者随机分为THP组和MMC组,每组34例,比较观察两组的复发和安全情况。结果 THP组6、12个月复发率分别为5.9%和8.8%明显低于MMC组的23.5%和32.4%(P<0.05),两组3个月复发率比较差异无统计学意义(P>0.05)。两组膀胱刺激症状、血尿、血象异常、肝功损害和肾功损害发生率比较,差异无统计学意义(P>0.05)。结论 THP与MMC均为术后浅表性膀胱癌进行膀胱灌注治疗的有效药物,不良反应少,而由于THP治疗后复发率相对较低,可作为临床一线用药。Objective To compare the effect of pirarubicin （THP） and mitomycin C （MMC）by bladder instillation in treatment with superficial bladder cancer. Methods From January 2009 to January 2011, 68 cases of superficial bladder cancer patients after transurethral resection were classified into THP group and MMC group, which each group with 34 cases, the tumor recurrent and safety between the two groups were compared. Results The recurrent rate at 6, 12 months were 5. 9% and 8. 8%, significantly lower than those in MMC group with 23.5% and 32.4% （ P 〈 0.05 ）, while no significant difference at 3 months be- tween two groups（ P 〉 0. 05 ）. There were no significant differences in incidences of bladder irritation, hematuria, blood abnormali- ties, liver damage and renal damage between two groups（ P 〉 O. 05 ）. Conclusion Both THP and MMC are effective drug for su- perficial bladder cancer with low side effects, but THP has relatively low recurrence rate and can be used for clinical first-line treatment.

关 键 词：吡柔比星 丝裂霉素 浅表性膀胱癌 

分 类 号：R737.14[医药卫生—肿瘤]